Current Value
$37.201 Year Return
Current Value
$37.201 Year Return
Double maintains 1 strategies that include APGE - Apogee Therapeutics, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SYRE | 53.16% | $938.50M | -54.33% | 0.00% |
KYMR | 52.75% | $1.97B | -5.94% | 0.00% |
CRNX | 52.15% | $2.86B | -32.73% | 0.00% |
KRYS | 50.81% | $3.63B | -22.27% | 0.00% |
ELVN | 50.81% | $870.49M | -21.30% | 0.00% |
ATXS | 49.87% | $279.35M | -45.06% | 0.00% |
IMNM | 48.38% | $778.76M | -39.16% | 0.00% |
DNLI | 48.09% | $1.97B | -26.65% | 0.00% |
IDYA | 48.08% | $1.76B | -43.98% | 0.00% |
DYN | 48.07% | $1.39B | -60.77% | 0.00% |
RCUS | 48.02% | $1.01B | -36.30% | 0.00% |
ACLX | 48.01% | $3.51B | +21.90% | 0.00% |
BEAM | 47.54% | $1.64B | -32.25% | 0.00% |
OCUL | 47.24% | $1.30B | +40.34% | 0.00% |
XNCR | 46.13% | $550.51M | -67.62% | 0.00% |
CLDX | 45.37% | $1.32B | -40.99% | 0.00% |
RVMD | 45.28% | $7.28B | +2.40% | 0.00% |
RGNX | 45.05% | $449.94M | -37.49% | 0.00% |
NRIX | 44.55% | $811.15M | -31.71% | 0.00% |
BLFS | 44.44% | $1.06B | +2.62% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FMTO | -17.88% | $37.82M | -99.94% | 0.00% |
K | -14.65% | $28.62B | +39.03% | 2.75% |
CBOE | -12.46% | $23.79B | +30.06% | 1.07% |
STG | -12.13% | $27.62M | -29.46% | 0.00% |
PULM | -12.05% | $29.95M | +345.65% | 0.00% |
VHC | -11.50% | $33.26M | +91.41% | 0.00% |
WBA | -9.39% | $9.72B | -27.00% | 4.47% |
VSTA | -9.36% | $326.42M | +15.63% | 0.00% |
AGL | -7.47% | $923.11M | -64.26% | 0.00% |
LITB | -7.02% | $24.46M | -56.54% | 0.00% |
KR | -6.52% | $44.58B | +28.80% | 1.91% |
AQB | -5.71% | $3.55M | -49.09% | 0.00% |
KO | -5.29% | $307.71B | +15.36% | 2.74% |
VSA | -5.03% | $6.89M | -41.29% | 0.00% |
VZ | -4.91% | $182.69B | +7.44% | 6.22% |
UUU | -4.64% | $5.57M | +52.53% | 0.00% |
RILY | -4.01% | $93.02M | -87.71% | 0.00% |
NEUE | -3.81% | $61.16M | +13.41% | 0.00% |
IMNN | -3.60% | $34.91M | +36.30% | 0.00% |
ED | -3.23% | $37.25B | +11.82% | 3.26% |
Yahoo
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 10:30 a.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology compa
Yahoo
The consensus price target hints at a 132.7% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Finnhub
SAN FRANCISCO, BOSTON - Apogee Therapeutics, Inc., , a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory...
Yahoo
Apogee Therapeutics, Inc. (NASDAQ:APGE) on Monday revealed interim data from its Phase 1b trial of APG808, a novel half-life extended IL-4Rα antibody, in patients with mild-to-moderate asthma. The Phase 1b double-blind, placebo-controlled, multiple-dose trial evaluated the safety and tolerability of APG808 in 22 adult patients with mild-to-moderate asthma. The trial also evaluated fractional exhaled nitric oxide concentration (FeNO), TARC, and pSTAT6. Participants were randomized 3:1, receiving
SeekingAlpha
Apogee Therapeutics, Inc. had promising results from its APG808 Phase 1b study show potential for every 2-month asthma treatment. Click for my APGE stock update.
Yahoo
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026 APG279 on track to initiate Phase 1b head-to-head trial vs DUPIXENT in 2025 with readout expected in 2H 2026 Positive interim Phase 1b readout of APG808 in patients with mild-to-moderate asthma demonstrated rapid, robust and sustained suppression o
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
UDN | -0.10% | $139.73M | 0.78% |
JPLD | -0.12% | $1.20B | 0.24% |
IBMN | -0.13% | $449.34M | 0.18% |
TDTT | -0.21% | $2.57B | 0.18% |
IEI | 0.35% | $15.84B | 0.15% |
SHYD | -0.47% | $321.41M | 0.35% |
FMF | -0.53% | $153.28M | 0.95% |
IBTH | 0.72% | $1.54B | 0.07% |
MLN | 0.76% | $528.48M | 0.24% |
IBTJ | 0.83% | $669.73M | 0.07% |
DFNM | 0.93% | $1.54B | 0.17% |
BWX | 1.01% | $1.42B | 0.35% |
UUP | -1.16% | $267.96M | 0.77% |
UGA | 1.28% | $70.86M | 0.97% |
LDUR | 1.29% | $911.83M | 0.5% |
JMST | -1.29% | $3.76B | 0.18% |
CLIP | 1.31% | $1.50B | 0.07% |
IBTI | -1.38% | $1.02B | 0.07% |
IBTG | -1.41% | $1.91B | 0.07% |
FXE | 1.68% | $523.55M | 0.4% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -36.74% | $320.45M | 1.43% |
VIXY | -35.62% | $141.70M | 0.85% |
TAIL | -33.84% | $111.21M | 0.59% |
FXY | -13.59% | $858.65M | 0.4% |
IVOL | -13.17% | $348.07M | 1.02% |
CTA | -10.67% | $1.08B | 0.76% |
ULST | -8.10% | $660.43M | 0.2% |
SHYM | -7.74% | $323.12M | 0.35% |
KCCA | -7.23% | $94.38M | 0.87% |
XONE | -6.69% | $616.52M | 0.03% |
SPTS | -6.04% | $5.74B | 0.03% |
CARY | -5.55% | $347.36M | 0.8% |
TPMN | -5.38% | $30.91M | 0.65% |
STPZ | -5.26% | $453.91M | 0.2% |
TBLL | -5.07% | $2.32B | 0.08% |
BSMW | -4.63% | $102.11M | 0.18% |
GBIL | -4.44% | $6.08B | 0.12% |
UTWO | -3.97% | $380.80M | 0.15% |
BILS | -3.87% | $3.94B | 0.1356% |
FTSD | -3.86% | $212.84M | 0.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 63.80% | $4.60B | 0.35% |
IBB | 57.02% | $5.23B | 0.45% |
PBE | 56.47% | $223.00M | 0.58% |
GNOM | 55.33% | $41.00M | 0.5% |
ARKG | 51.37% | $927.51M | 0.75% |
IWC | 51.19% | $784.70M | 0.6% |
IWO | 50.58% | $11.24B | 0.24% |
FBT | 49.51% | $1.03B | 0.56% |
BBH | 49.07% | $330.20M | 0.35% |
VTWO | 48.91% | $12.05B | 0.07% |
IWM | 48.72% | $63.57B | 0.19% |
KJUL | 47.98% | $115.62M | 0.79% |
SCHA | 47.84% | $16.81B | 0.04% |
PINK | 47.61% | $130.02M | 0.5% |
NUSC | 47.33% | $1.10B | 0.31% |
PTH | 47.29% | $97.74M | 0.6% |
ISCG | 47.20% | $658.37M | 0.06% |
KJAN | 47.07% | $300.25M | 0.79% |
VBK | 46.69% | $18.20B | 0.07% |
ESML | 46.41% | $1.80B | 0.17% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PPC | -0.13% | $11.62B | +54.56% | 0.00% |
MSIF | -0.27% | $734.58M | +55.89% | 6.87% |
AEP | -0.36% | $54.77B | +16.30% | 3.58% |
CVS | -0.56% | $79.42B | +12.03% | 4.23% |
MCK | -0.67% | $89.19B | +27.08% | 0.39% |
BPT | 0.74% | $13.51M | -73.14% | 0.00% |
ZCMD | 0.81% | $28.19M | -6.20% | 0.00% |
EXC | -0.89% | $44.12B | +18.98% | 3.56% |
KMB | 1.08% | $47.73B | +10.93% | 3.43% |
CHD | 1.26% | $24.17B | -5.96% | 1.18% |
HOLX | 1.31% | $14.02B | -13.31% | 0.00% |
RPRX | -1.35% | $13.75B | +23.68% | 2.63% |
FATBB | 1.47% | $47.18M | -21.30% | 10.58% |
SYPR | -1.60% | $46.65M | +36.24% | 0.00% |
CME | -1.70% | $103.02B | +39.52% | 3.67% |
ARLP | 1.73% | $3.35B | +9.22% | 10.77% |
HEES | 2.00% | $3.49B | +100.67% | 1.16% |
COKE | 2.01% | $8.91B | +16.00% | 7.07% |
COR | -2.13% | $56.34B | +31.81% | 0.74% |
T | -2.21% | $197.02B | +55.39% | 4.06% |